Get the Stockscreener App
0.00
100.00%
-18.20
Reneo Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
See More
Previous Close:
$18.20
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$6.08M
Revenue:
-
Net Income/Loss:
$-77.39M
P/E Ratio:
0.00
EPS:
-2.53
Net Cash Flow:
$-63.90M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$19.30
Reneo Pharmaceuticals Inc Stock (RPHM) Company Profile
Name
Reneo Pharmaceuticals Inc
Sector
Industry
Phone
(858) 283-0280
Address
18575 JAMBOREE ROAD, IRVINE
Compare RPHM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPHM
Reneo Pharmaceuticals Inc
|
0.00 | 6.08M | 0 | -77.39M | -63.90M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Reneo Pharmaceuticals Inc Stock (RPHM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Initiated | Leerink Partners | Outperform |
| Oct-10-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-15-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-14-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-23 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Dec-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-14-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-15-23 | Initiated | William Blair | Outperform |
| Aug-28-23 | Initiated | H.C. Wainwright | Buy |
| Jul-03-23 | Initiated | BofA Securities | Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jan-27-22 | Initiated | Robert W. Baird | Outperform |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-22-21 | Initiated | Ladenburg Thalmann | Buy |
| May-04-21 | Initiated | Jefferies | Buy |
| May-04-21 | Initiated | Piper Sandler | Overweight |
| May-04-21 | Initiated | SVB Leerink | Outperform |
View All
Reneo Pharmaceuticals Inc Stock (RPHM) Latest News
Reneo Pharmaceuticals stock hits 52-week low at $7.64 - Investing.com India
Reneo Pharmaceuticals stock hits 52-week low at $7.91 By Investing.com - Investing.com Nigeria
Reneo Pharmaceuticals stock hits 52-week low at $7.91 - Investing.com
OnKure Therapeutics Reports Strategic Merger and Financial Updates - TipRanks
Head to Head Survey: OnKure Therapeutics (OKUR) vs. Its Rivals - Defense World
Analysis of TANG CAPITAL MANAGEMENT LLC's Recent Transaction in Reneo Pharmaceuticals Inc - GuruFocus.com
Highbridge Capital Management LLC Increases Stake in Reneo Pharm - GuruFocus.com
Form 424B3 OnKure Therapeutics, - StreetInsider.com
Reneo Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Reneo Pharmaceuticals (NASDAQ:RPHM) Stock Price Up 5.2% – Here’s What Happened - Defense World
Octagon Capital Advisors LP Adjusts Stake in Reneo Pharmaceutica - GuruFocus.com
Deep Track Capital, LP's Strategic Acquisition in Reneo Pharmace - GuruFocus.com
Analysts Offer Predictions for OKUR Q1 Earnings - Defense World
What is HC Wainwright's Estimate for OKUR Q1 Earnings? - MarketBeat
OnKure Therapeutics (NASDAQ:OKUR) Earns Buy Rating from HC Wainwright - MarketBeat
OnKure Therapeutics (OKUR) Stock Rebounds In Extended Session - Stocks Telegraph
Cormorant Asset Management's Strategic Acquisition of Reneo Pharmaceuticals Shares - Yahoo Finance
Deep Track Capital's Strategic Investment in Reneo Pharmaceuticals - Yahoo Finance
Deep Track Capital's Strategic Investment in Reneo Pharmaceutica - GuruFocus.com
OnKure shares initiated with Outperform rating on drug potential - Investing.com India
Perceptive Advisors LLC Acquires New Stake in Reneo Pharmaceuticals Inc - Yahoo Finance
Carlyle Group Inc. Reduces Stake in Reneo Pharmaceuticals Inc. - GuruFocus.com
Recently Listed Cancer Firm OnKure’s Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines
OnKure shares initiated with Outperform rating on drug potential By Investing.com - Investing.com Canada
Reneo Pharmaceuticals Completes Merger and Name Change to OnKure Therapeutics, Inc. - MarketBeat
Reneo Pharmaceuticals: Navigating Financial Challenges and Corporate Changes - TipRanks
Newley merged OnKure raises $65 million - The Pharma Letter
Boulder’s OnKure goes public with merger; key drug trial underway - Boulder Daily Camera
OnKure and Reneo Pharmaceuticals complete merger - Yahoo Finance
Reneo Pharmaceuticals stockholders approval merger with OnKure - TipRanks
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million - ForexTV.com
Reneo stockholders approve merger with OnKure - MSN
Reneo Pharmaceuticals secures stockholder approval for OnKure merger By Investing.com - Investing.com Australia
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure - StockTitan
Reneo Pharmaceuticals' Shareholders Approve Merger With OnKure; Reverse Stock Split Imminent - Marketscreener.com
Reneo Pharmaceuticals secures stockholder approval for OnKure merger - Investing.com India
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure - Benzinga
Point72 Asia Singapore Pte. Ltd. Takes Position in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) - Defense World
Nantahala Capital Management LLC Invests $846,000 in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) - Defense World
Reneo Pharmaceuticals Inc [RPHM] stock for 102,872 USD was bought by Leonard Braden Michael - Knox Daily
Braden Michael Leonard Purchases 29,600 Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Stock - MarketBeat
Reneo Pharmaceuticals executive buys shares worth over $144k - Investing.com India
Reneo Pharmaceuticals executive buys shares worth over $144k By Investing.com - Investing.com Canada
Reneo Pharmaceuticals Inc Stock (RPHM) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.02%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):